Form 4 for YARW Yarrow Bioscience, Inc.
Accepted 2021-09-03 00:00:00 ET · period of report 2021-09-02 · accession 0001209191-21-054833 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-03 | 2021-09-02 | YARW | Domzalski David | Pres, CEO, Dir | A - Grant | $0.00 | +320.3K | 775.9K | +70% | $0 |
| D | 2021-09-03 | 2021-09-02 | YARW | Domzalski David | Pres, CEO, Dir | A - Grant | $0.00 | +320.3K | 320.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-02 | A | A | 320,312 | $0.00 | 775,911 | D | — | — | (F1) Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date. |
| 2 | Derivative | Stock Options | 2021-09-02 | A | A | 320,313 | $0.00 | 320,313 | D | $1.68 · — to 2031-09-02 | 320,313 Common Stock | (F2) 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date. |